The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
Open accessAbstract
BACKGROUND: Romosozumab is a monoclonal antibody that binds to and inhibits sclerostin, increases bone formation, and decreases bone resorption. METHODS: We enrolled 4093 postmenopausal women with osteoporosis and a fragility fracture and randomly assigned them in a 1:1 ratio to receive monthly subcutaneous romosozumab (210 mg) or weekly oral alendronate (70 mg) in a blinded fashion for 12 months, followed by open-label alendronate in both groups. The primary end points were the cumulative incidence of new vertebral fracture at 24 months and the cumulative incidence of clinical fracture (nonvertebral and symptomatic vertebral fracture) at the time of the primary analysis (after clinical fractures had been confirmed in ≥330 patients). Secondary end points included the incidences of nonvertebral and hip fracture at the time of the primary analysis. Serious cardiovascular adverse events, osteonecrosis of the jaw, and atypical femoral fractures were adjudicated. RESULTS: Over a period of 24 months, a 48% lower risk of new vertebral fractures was observed in the romosozumab-to-alendronate group (6.2% [127 of 2046 patients]) than in the alendronate-to-alendronate group (11.9% [243 of 2047 patients]) (P<0.001). Clinical fractures occurred in 198 of 2046 patients (9.7%) in the romosozumab-to-alendronate group versus 266 of 2047 patients (13.0%) in the alendronate-to-alendronate group, representing a 27% lower risk with romosozumab (P<0.001). The risk of nonvertebral fractures was lower by 19% in the romosozumab-to-alendronate group than in the alendronate-to-alendronate group (178 of 2046 patients [8.7%] vs. 217 of 2047 patients [10.6%]; P=0.04), and the risk of hip fracture was lower by 38% (41 of 2046 patients [2.0%] vs. 66 of 2047 patients [3.2%]; P=0.02). Overall adverse events and serious adverse events were balanced between the two groups. During year 1, positively adjudicated serious cardiovascular adverse events were observed more often with romosozumab than with alendronate (50 of 2040 patients [2.5%] vs. 38 of 2014 patients [1.9%]). During the open-label alendronate period, adjudicated events of osteonecrosis of the jaw (1 event each in the romosozumab-to-alendronate and alendronate-to-alendronate groups) and atypical femoral fracture (2 events and 4 events, respectively) were observed. CONCLUSIONS: In postmenopausal women with osteoporosis who were at high risk for fracture, romosozumab treatment for 12 months followed by alendronate resulted in a significantly lower risk of fracture than alendronate alone. (Funded by Amgen and others; ARCH ClinicalTrials.gov number, NCT01631214 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, major cardiac events were observed in the ARCH study, while headaches, arthralgia, and injection site reactions were also observed [89,90].”
From Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics (2023) · cites this paper as [89]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“As of 2021, it has reached Phase III trials, which have shown an increase in bone mineral density and a decrease in vertebral and hip fractures.”
From Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics (2023) · cites this paper as [89]
The cited source says what the claim attributes to it.
In the citing paper
“The ARCH study showed a 48% lower risk of new vertebral fractures in the group that received romosozumab and alendronate than in the alendronate-only group [89].”
From Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics (2023) · cites this paper as [89]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Epidemiology and outcomes of osteoporotic fractures
Cummings, S. R., & Melton, L. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08657-9 · Cited by 3,821
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
Cosman, F., Crittenden, D. B., Adachi, J. D., Binkley, N., Czerwinski, E., Ferrari, S., Hofbauer, L. C., Lau, E., Lewiecki, E. M., Miyauchi, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607948 · Cited by 1,805
Self-citationReginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Self-citationRomosozumab in Postmenopausal Women with Low Bone Mineral Density
McClung, M. R., Grauer, A., Boonen, S., Bolognese, M. A., Brown, J. P., Diez-Perez, A., Langdahl, B. L., Reginster, J.-Y., Zanchetta, J. R., Wasserman, S. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1305224 · Cited by 1,258
Self-citationBrunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y.-H., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318811 · Cited by 1,011
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 1,000
Hu, M., Zhang, Y., Guo, J., Guo, C., Yang, X., Ma, X., Xu, H., & Xiang, S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1188969 · Cited by 19
Sequential management of postmenopausal health and osteoporosis: An update
Calaf, J., Cano, A., Guañabens, N., Palacios, S., Hidalgo, M. J. C., Castelo‐Branco, C., Larrainzar‐Garijo, R., Neyro, J. L., Nogués, X., & Díez‐Pérez, A. (2023) · Maturitas · doi:10.1016/j.maturitas.2023.107846 · Cited by 19
Emerging Landscape of Osteogenesis Imperfecta Pathogenesis and Therapeutic Approaches
Sun, Y., Li, L., Wang, J., Liu, H., & Wang, H. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00324 · Cited by 20
Tripto‐Shkolnik, L., Szalat, A., Tsvetov, G., Rouach, V., Sternberg, C., Hoppe, A., Burshtein, G., Galitzer, H., Toledano, M., Harari, G., et al. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae057 · Cited by 19
Efficacy and safety of romosozumab: a meta-analysis of placebo-controlled trials
Kobayashi, T., Hara, M., Shimanoe, C., Morimoto, T., Mawatari, M., Ito, K., & Shimazaki, T. (2024) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-024-01531-5 · Cited by 19
Wong, R. M. Y., Wong, P. Y., Liu, C., Wong, H. Y., Fong, M. K., Zhang, N., Cheung, W., & Law, S. W. (2024) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2024.07.011 · Cited by 19
Laser irradiation decreases sclerostin expression in bone and osteogenic cells
Ohsugi, Y., Katagiri, S., Hirota, T., Niimi, H., Hatasa, M., Watanabe, K., Shimohira, T., Mizutani, K., Kitazawa, M., Matsuzawa, A., et al. (2020) · The FASEB Journal · doi:10.1096/fj.202001032r · Cited by 19
Kline, G. A., Lix, L. M., & Leslie, W. D. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4333 · Cited by 19
Exercise for Postmenopausal Bone Health – Can We Raise the Bar?
Kumar, S., Smith, C., Clifton-Bligh, R. J., Beck, B. R., & Girgis, C. M. (2025) · Current Osteoporosis Reports · doi:10.1007/s11914-025-00912-7 · Cited by 21
Leder, B. Z., Ramchand, S. K., Jordan, M., Ryan, S., Patnaik, A., Lee, H., & Tsai, J. N. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00319-5 · Cited by 18
Deciphering novel chemotherapy and its impact on dentistry
King, R., Zebic, L., & Patel, V. (2020) · BDJ · doi:10.1038/s41415-020-1365-5 · Cited by 19
Osteoanabolic therapy for osteoporosis in women
McClung, M. R., & Clark, A. (2021) · Climacteric · doi:10.1080/13697137.2021.1953463 · Cited by 18
Pathogenesis and treatment of multiple myeloma bone disease
Hiasa, M., Harada, T., Tanaka, E. I., & Abe, M. (2021) · Japanese Dental Science Review · doi:10.1016/j.jdsr.2021.08.006 · Cited by 18
The role of osteoanabolic agents in the management of patients with osteoporosis
McClung, M. R., Rothman, M. S., Lewiecki, E. M., Hanley, D. A., Harris, S. T., Miller, P. D., & Kendler, D. L. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2069582 · Cited by 19
Bone fragility: conceptual framework, therapeutic implications, and COVID-19-related issues
Iolascon, G., Paoletta, M., Liguori, S., Gimigliano, F., & Moretti, A. (2022) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x221133429 · Cited by 18
Lim, S. Y., & Bolster, M. B. (2022) · International Journal of Women s Health · doi:10.2147/ijwh.s315184 · Cited by 18
Xiao, Y., Chen, Y., Huang, Y., & Yuan, X. (2023) · Scientific Reports · doi:10.1038/s41598-023-37944-x · Cited by 20
Sclerostin: clinical insights in muscle–bone crosstalk
Moretti, A., & Iolascon, G. (2023) · Journal of International Medical Research · doi:10.1177/03000605231193293 · Cited by 18
Han, Y., Mo, Y.-Y., Wu, H., Iqbal, J., Cai, J., Li, L., Bu, Y., Xiao, F., Jiang, H., Wen, Y., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102425 · Cited by 19
Gubu, A., Ma, Y., Yu, S., Zhang, H., Chen, Z., Ni, S., Abdullah, R., Xiao, H., Zhang, Y., Dai, H., et al. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102146 · Cited by 18
Glucocorticoid-induced osteoporosis—from molecular mechanism to clinical practice
Hsu, C. H., Hsu, C. L., Langley, A., Wojcik, C., Iraganje, E., & Grygiel‐Górniak, B. (2024) · Drugs & Therapy Perspectives · doi:10.1007/s40267-024-01079-4 · Cited by 19
Osteoporosis Evaluation and Management in Spine Surgery
Girdler, S. J., Lindsey, M. H., Sebastian, A. S., & Nassr, A. N. (2024) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/jaaos-d-24-00311 · Cited by 18
Management of fracture risk in patients with diabetes—Chinese Expert Consensus
Liu, J., Zhu, D., Mu, Y., & Xia, W. (2019) · Journal of Diabetes · doi:10.1111/1753-0407.12962 · Cited by 18
Lim, K., Bullock, W. A., Horan, D. J., Williams, B. O., Warman, M. L., & Robling, A. G. (2020) · Bone · doi:10.1016/j.bone.2020.115708 · Cited by 19
Shimizu, T., Arita, K., Murota, E., Hiratsuka, S., Fujita, R., Ishizu, H., Asano, T., Takahashi, D., Takahata, M., & Iwasaki, N. (2021) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-021-01226-1 · Cited by 18
Geusens, P., Feldman, R., Oates, M. K., Thomas, T., Makras, P., Jakob, F. J., Langdahl, B. L., Wang, Z., Rojeski, M., & Libanati, C. R. (2021) · Bone · doi:10.1016/j.bone.2021.116209 · Cited by 18
Self-citationOsteoporosis: Epidemiology, Pathogenesis, Evaluation and Treatment
Chadha, M. D., Chaddha, R., Divakar, H., Kalyan, H. K., Seth, S., & Shah, P. (2022) · Open Journal of Orthopedics · doi:10.4236/ojo.2022.124016 · Cited by 18
Romosozumab, clinical trials, and real-world care of patients with osteoporosis
Lewiecki, E. M. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.03.196 · Cited by 18
The Dual Role and Therapeutic Implications of the Wnt/β-Catenin Pathway in Diabetic Kidney Disease
Adeerjiang, Y., Gan, X.-X., Li, W., Li, Q., Jiang, Y., Xia Shuang, Z. H. U., Hu, C.-M., Wang, P., & Jiang, S. (2025) · International Journal of General Medicine · doi:10.2147/ijgm.s524138 · Cited by 17
Operationalizing Treat-to-Target for Osteoporosis
Lewiecki, E. M. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.970 · Cited by 17
The roles of hepatokine and osteokine in liver-bone crosstalk: Advance in basic and clinical aspects
Li, Z., Wen, X., Li, N., Zhong, C., Chen, L., Zhang, F., Zhang, G., Lü, A., & Liu, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1149233 · Cited by 17
An angiogenic approach to osteoanabolic therapy targeting the SHN3-SLIT3 pathway
Yallowitz, A. R., Shim, J., Xu, R., & Greenblatt, M. B. (2023) · Bone · doi:10.1016/j.bone.2023.116761 · Cited by 17
Corrao, G., Biffi, A., Porcu, G., Ronco, R., Adami, G., Alvaro, R., Bogini, R., Caputi, A. P., Cianferotti, L., Frediani, B., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1137671 · Cited by 18
Self-citationFlorio, M., Kostenuik, P. J., Stolina, M., Asuncion, F., Grisanti, M. S., Ke, H. Z., & Ominsky, M. S. (2023) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.22.01092 · Cited by 17
Osteoimmunology of Spondyloarthritis
Fassio, A., Atzeni, F., Rossini, M., D’Amico, V., Cantatore, F. P., Chimenti, M. S., Crotti, C., Frediani, B., Giusti, A., Peluso, G., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914924 · Cited by 18
Gielen, E., Aldvén, M., Kanis, J. А., Borgström, F., Senior, E., & Willems, D. (2024) · Osteoporosis International · doi:10.1007/s00198-024-07043-2 · Cited by 17
Romosozumab versus parathyroid hormone receptor agonists: which osteoanabolic to choose and when?
Anastasilakis, A. D., Yavropoulou, M. P., Palermo, A., Makras, P., Paccou, J., Tabacco, G., Naciu, A. M., & Tsourdi, E. A. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae076 · Cited by 17
Kawazoe, M., Kaneko, K., Masuoka, S., Yamada, S., Yamada, Z., Muraoka, S., Furukawa, K., Sato, H., Watanabe, E., Koshiba, K., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae810 · Cited by 17
Proceedings of the 2018 Santa Fe Bone Symposium: Advances in the Management of Osteoporosis
Lewiecki, E. M., Bilezikian, J. P., Giangregorio, L., Greenspan, S. L., Khosla, S., Kostenuik, P. J., Krohn, K., McClung, M. R., Miller, P. D., & Pacifici, R. (2018) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2018.09.010 · Cited by 17
Osteocalcin and sclerostin: Background characters or main actors in cardiovascular disease?
D’Onofrio, L., Maddaloni, E., & Buzzetti, R. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3217 · Cited by 17
Mariscal, G., Núñez, J. H., Bhatia, S., Barrios, C., & Domenech-Fernández, P. (2020) · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy · doi:10.1089/mab.2019.0049 · Cited by 17
de Oliveira, P. A. P., Montenegro, A. C., Bezerra, L. R. A., de Lemos, M. D. C. C., & Bandeira, F. A. F. (2020) · Obesity Surgery · doi:10.1007/s11695-020-04625-x · Cited by 17
Hagino, H., Tanaka, K., Silverman, S. L., McClung, M. R., Gandra, S., Charokopou, M., Adachi, K., Johnson, B., & Stollenwerk, B. (2021) · Osteoporosis International · doi:10.1007/s00198-021-05927-1 · Cited by 17
Update on bone health: the International Menopause Society White Paper 2021
de Villiers, T. J., & Goldstein, S. R. (2021) · Climacteric · doi:10.1080/13697137.2021.1950967 · Cited by 17
Synergistic Effect of Whitlockite Scaffolds Combined with Alendronate to Promote Bone Regeneration
Jeong, J., Shim, J. H., Koo, B. M., Choy, Y. B., & Heo, C. Y. (2021) · Tissue Engineering and Regenerative Medicine · doi:10.1007/s13770-021-00416-2 · Cited by 17
Peptide modified geniposidic acid targets bone and effectively promotes osteogenesis
Liu, M., Zhu, D., Jin, F., Li, S., Liu, X., & Wang, X. (2022) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2022.07.007 · Cited by 17
Osteocytes: New Kids on the Block for Cancer in Bone Therapy
Anloague, A., & Delgado‐Calle, J. (2023) · Cancers · doi:10.3390/cancers15092645 · Cited by 17
Möckel, L., Bartneck, M., & Möckel, C. (2020) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2020.02.003 · Cited by 17
Molecular Mechanisms of New Bone Formation in Axial Spondyloarthritis
Klavdianou, K., Kanellou, A., & Daoussis, D. (2022) · Mediterranean Journal of Rheumatology · doi:10.31138/mjr.33.1.115 · Cited by 19
Sclerostin's role in bone–muscle crosstalk and osteoporosis pathogenesis
Shahid, H., Morya, V. K., & Noh, K.-C. (2025) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2025.06.004 · Cited by 17
Parathyroid hormone 1 receptor signaling mediates breast cancer metastasis to bone in mice
Swami, S., Zhu, H., Nisco, A., Kimura, T., Kim, M., Nair, V., & Wu, J. Y. (2023) · JCI Insight · doi:10.1172/jci.insight.157390 · Cited by 16
Hong, N., Shin, S., Lee, S., & Rhee, Y. (2023) · Osteoporosis International · doi:10.1007/s00198-023-06889-2 · Cited by 16
Miyauchi, A., Hamaya, E., Shimauchi, J., Yoshinaga, Y., & Nishi, K. (2023) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-023-01477-0 · Cited by 16
Mineta, K., Nishisho, T., Okada, M., Kamada, M., & Sairyo, K. (2024) · Bone · doi:10.1016/j.bone.2024.117164 · Cited by 16
Kobayakawa, T., Kanayama, Y., Hirano, Y., Yukishima, T., & Nakamura, Y. (2024) · JBMR Plus · doi:10.1093/jbmrpl/ziae131 · Cited by 16
Revisiting osteoporosis guidelines
Reid, I. R. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00283-7 · Cited by 16
Immediate Risk for Cardiovascular Events in Hip Fracture Patients: A Population-Based Cohort Study
Hsu, W. W. Q., Sing, C., Li, G. H., Tan, K. C. B., Cheung, B. M. Y., Wong, J. S. H., Wong, I. C. K., & Cheung, C. (2021) · The Journals of Gerontology Series A · doi:10.1093/gerona/glab336 · Cited by 16
Dual Targeting Anti-Osteoporotic Therapy Through Potential Nanotherapeutic Approaches
Salave, S., Rana, D., & Benival, D. M. (2022) · Pharmaceutical Nanotechnology · doi:10.2174/2211738510666220902124653 · Cited by 16
Lewiecki, E. M., Bilezikian, J. P., Bukata, S. V., Camacho, P. M., Clarke, B. L., McClung, M. R., Miller, P. D., & Shepherd, J. (2017) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2017.01.001 · Cited by 16
Williams, D. K., Parham, S. G., Schryver, E. M., Akel, N. S., Shelton, R. S., Webber, J. S., Swain, F. L., Schmidt, J., Suva, L. J., & Gaddy, D. (2017) · JBMR Plus · doi:10.1002/jbm4.10025 · Cited by 16
Western Osteoporosis Alliance Clinical Practice Series: Treat-to-Target for Osteoporosis
Lewiecki, E. M., Kendler, D. L., Davison, K. S., Hanley, D. A., Harris, S. T., McClung, M. R., & Miller, P. D. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.04.044 · Cited by 16
Jörg, D. J., Fuertinger, D. H., Cherif, A., Bushinsky, D. A., Mermelstein, A., Raimann, J. G., & Kotanko, P. (2022) · eLife · doi:10.7554/elife.76228 · Cited by 15
Chiu, S.-H., Wu, W., Yao, T.-K., Peng, C.-H., & Yeh, K. (2024) · Biomedicines · doi:10.3390/biomedicines12122880 · Cited by 17
Management of osteoporosis in chronic kidney disease
Henry, N., Hildebrand, S., & Cunningham, J. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf228 · Cited by 15
Willems, D., Javaid, M. K., Pinedo‐Villanueva, R., Libanati, C. R., Yehoshua, A., & Charokopou, M. (2022) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.11.015 · Cited by 15
Mace, M. L., Gravesen, E., Nordholm, A., Egstrand, S., Morevati, M., Ølgaard, K., & Lewin, E. (2022) · JBMR Plus · doi:10.1002/jbm4.10610 · Cited by 15
Wei, F., Gao, Q.-Y., Zhu, K.-L., Wei, H., Du, M., Yang, F., Gao, H.-R., Li, T., Qian, J., & Zhou, C.-P. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e11880 · Cited by 15
Kocełak, P., Puzianowska‐Kuźnicka, M., Olszanecka‐Glinianowicz, M., & Chudek, J. T. (2023) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/169567 · Cited by 15
Pfeil, A., & Lange, U. (2024) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-024-01495-x · Cited by 15
Lorentzon, M., Litsne, H., & Axelsson, K. F. (2024) · Osteoporosis International · doi:10.1007/s00198-024-07072-x · Cited by 15
Self-citationJeon, I., Park, S. B., Moon, B. J., Choi, M., Kuh, S. U., & Kim, J. (2024) · Neurospine · doi:10.14245/ns.2347256.628 · Cited by 15
Borgström, F., Lorentzon, M., Johansson, H., Harvey, N. C., McCloskey, E., Willems, D., Knutsson, D., & Kanis, J. A. (2024) · Osteoporosis International · doi:10.1007/s00198-024-07251-w · Cited by 15
Self-citationAlcalde‐Herraiz, M., Xie, J., Newby, D., Prats, C., Gill, D., Gordillo‐Marañón, M., Prieto‐Alhambra, D., Català, M., & Prats‐Uribe, A. (2024) · Nature Communications · doi:10.1038/s41467-024-53623-5 · Cited by 15
Advances in osteoporosis from 1970 to 2018
Gallagher, J. C. (2018) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001263 · Cited by 16
Yooin, W., Saenjum, C., Ruangsuriya, J., & Jiranusornkul, S. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1599427 · Cited by 15
Sclerostin within the chronic kidney disease spectrum
Bouquegneau, A., Evenepoel, P., Paquot, F., Malaise, O., Cavalier, E., & Delanaye, P. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.12.008 · Cited by 17
Nakagawa, Y., Komaba, H., Hamano, N., Tanaka, H., Wada, T., Ishida, H., Nakamura, M., Takahashi, H., Takahashi, Y., Hyodo, T., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab623 · Cited by 16
Romosozumab and cardiovascular safety in Japan
Takeuchi, Y. (2021) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2021.09.002 · Cited by 15
Poutoglidou, F., Samoladas, E., Raikos, Ν., & Kouvelas, D. (2021) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2021.11.005 · Cited by 15
Rodríguez, A. J., & Abrahamsen, B. (2021) · JBMR Plus · doi:10.1002/jbm4.10522 · Cited by 15
Assessment and management of imminent fracture risk in the setting of the fracture liaison service
Javaid, M. K., Harvey, N. C., McCloskey, E. V., Kanis, J. А., & Cooper, C. C. (2022) · Osteoporosis International · doi:10.1007/s00198-021-06284-9 · Cited by 15
What is the risk of cardiovascular events in osteoporotic patients treated with romosozumab?
Reid, I. R. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2160445 · Cited by 15
Hatano, M., Sasabuchi, Y., Okada, A., Kimura, Y., Ishikura, H., Tanaka, T., Saito, T., Tanaka, S., & Yasunaga, H. (2025) · Annals of the Rheumatic Diseases · doi:10.1016/j.ard.2025.06.2124 · Cited by 14
Bisphosphonates in the Management of Patients with Postmenopausal Osteoporosis; Back to the Future
Papapoulos, S. E., & Makras, P. (2025) · Pharmaceuticals · doi:10.3390/ph18071068 · Cited by 16
Dong, H., Liu, R., Zou, K., Jin, Z., Kang, J., Zhang, Y., Zhang, X., Sun, Z., Yu, G., Huang, N., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4800 · Cited by 14
Lane, N. E., Betah, D., Deignan, C., Oates, M. K., Wang, Z., Timoshanko, J., Khan, A. A., & Binkley, N. (2023) · ACR Open Rheumatology · doi:10.1002/acr2.11619 · Cited by 14
Lane, J. M., Langdahl, B. L., Stone, M. D., Kurth, A., Oates, M. K., Timoshanko, J., Wang, Z., Libanati, C. R., & Cosman, F. (2024) · Osteoporosis International · doi:10.1007/s00198-024-07049-w · Cited by 14
A practical approach for anabolic treatment of bone fragility with romosozumab
Cianferotti, L., Cipriani, C., Palermo, A., Viapiana, O., Zavatta, G., & Mazziotti, G. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02395-2 · Cited by 14
A comprehensive review and advanced biomolecule-based therapies for osteoporosis
Ali, M., & Kim, Y. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.05.024 · Cited by 15
Lin, C., Yang, Y.-S., Ma, H., Chen, Z., Chen, D., John, A. A., Xie, J., Gao, G., & Shim, J. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.06.036 · Cited by 14
Recent progress in metal-catalyzed C(sp³)-P bond formation
Tu, J., Shen, Z., & Huang, B. (2024) · Tetrahedron · doi:10.1016/j.tet.2024.134352 · Cited by 14
Clinical Utility of Bone Turnover Markers in Chronic Kidney Disease
Srisuwarn, P., Eastell, R., & Salam, S. (2024) · Journal of Bone Metabolism · doi:10.11005/jbm.24.789 · Cited by 14
Cardiovascular outcomes of romosozumab treatment—real-world data analysis
Tsur, A., Cahn, A., Levy, L., & Pollack, R. M. (2024) · JBMR Plus · doi:10.1093/jbmrpl/ziae146 · Cited by 14
Yukishima, T., Ebina, K., Etani, Y., Noguchi, T., Ohmura, S., Nakata, K., Okada, S., & Kobayakawa, T. (2025) · Osteoporosis International · doi:10.1007/s00198-025-07386-4 · Cited by 14
Sequential and combination therapy with romosozumab
Kobayakawa, T. (2025) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-025-01590-2 · Cited by 14
Advancing care: optimizing osteoporosis treatment in the older and oldest old population
Panait, C., & D’Amelio, P. (2025) · Aging Clinical and Experimental Research · doi:10.1007/s40520-025-02973-1 · Cited by 14
Söreskog, E., Borgström, F., Lindberg, I., Ström, O., Willems, D., Libanati, C. R., Kanis, J. А., Stollenwerk, B., & Charokopou, M. (2021) · Osteoporosis International · doi:10.1007/s00198-020-05765-7 · Cited by 14
Henssler, L., Kerschbaum, M., Mukashevich, M. Z., Rupp, M., & Alt, V. (2021) · Injury · doi:10.1016/j.injury.2021.04.068 · Cited by 14
Endocrinology of bone mineralization: An update
Jannin, A., Kerlan, V., & Desailloud, R. (2021) · Annales d Endocrinologie · doi:10.1016/j.ando.2021.12.001 · Cited by 14
Pinedo‐Villanueva, R., Burn, E., Maronga, C., Cooper, C. C., & Javaid, M. K. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4775 · Cited by 14
Metadata
- Authors
- Saag, K. G., Petersen, J., Brandi, M. L., Karaplis, A. C., Lorentzon, M., Thomas, T., Maddox, J., Fan, M., Meisner, P. D., & Grauer, A.
- Affiliations
- Inserm (FR)
- Amgen (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-10-12
- Volume
- 377
- Issue
- 15
- Pages
- 1417-1427
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2754720807
- Cited by
- 1,544
- References
- 31
- Citations by year
- 2026: 204 · 2025: 216 · 2024: 210 · 2023: 148 · 2022: 179 · 2021: 172 · 2020: 185 · 2019: 114 · 2018: 94 · 2017: 19
- FWCI
- 123.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Florence Research (University of Florence) (submittedVersion, other-oa)
- Research Bank (Australian Catholic University) (submittedVersion)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Gilead Sciences
- Teva Pharmaceutical Industries
- Radius Health
- Medac
- Chugai Pharmaceutical
- Amgen Canada
- UCB Pharma
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- romosozumab, alendronate, osteoporosis, fracture prevention, sclerostin inhibition, postmenopausal women, vertebral fractures, hip fracture, non-vertebral fractures, bisphosphonates, cardiovascular adverse events, osteonecrosis of the jaw, atypical femoral fractures, bone formation, bone resorption, fragility fractures, open-label extension
- MeSH terms
- Aged, Antibodies, Monoclonal, Cardiovascular Diseases, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Risk, Bone Density, Osteoporosis, Postmenopausal, Incidence, Least-Squares Analysis, Spinal Fractures, Bone Remodeling, Alendronate, Bone Density Conservation Agents, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
